The Schall Law Firm Investigates Voyager Therapeutics, Inc. for Potential Securities Law Violations
Los Angeles, CA – Feb. 21, 2025
The Schall Law Firm, a renowned national shareholder rights litigation firm, has announced that it is investigating potential securities laws violations by Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ: VYGR). The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose material information to investors.
Background on Voyager Therapeutics, Inc.
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological and neurodegenerative diseases. The Company’s primary therapeutic approach is to develop and commercialize engineered AAV (Adeno-Associated Virus) gene therapies for various diseases, including Parkinson’s disease, Huntington’s disease, and spinal muscular atrophy.
Alleged Misconduct and Concerns
The Schall Law Firm’s investigation comes after a series of events that have raised concerns among investors. These events include:
-
The Company’s announcement of disappointing clinical trial results for its VY-AADC program, designed to treat Parkinson’s disease, in December 2024.
-
The departure of the Company’s Chief Medical Officer and several other key executives in early 2025.
-
Rumors and reports of potential regulatory issues with the Company’s gene therapy programs.
The Schall Law Firm believes that if these allegations are true, investors may have been misled and may be entitled to compensation.
Impact on Individual Investors
If the allegations against Voyager Therapeutics are proven, it could result in significant financial losses for individual investors. The Company’s stock price has already seen a sharp decline following the disappointing clinical trial results and executive departures. Further losses could occur if the Company faces regulatory action or additional negative news.
Impact on the World and the Biotech Industry
The potential securities law violations at Voyager Therapeutics could have far-reaching consequences, going beyond just the Company and its investors. The biotech industry as a whole could face increased scrutiny and potential regulatory action. This could lead to a decrease in investor confidence in the sector and a slowdown in innovation and investment.
Conclusion
The Schall Law Firm’s investigation into Voyager Therapeutics, Inc. is a reminder of the importance of transparency and honesty in the business world. If the allegations against the Company are proven, it could result in significant financial losses for investors and a negative impact on the biotech industry. As always, investors are encouraged to consult with a securities attorney or financial advisor to discuss their options and protect their investments.
The Schall Law Firm is dedicated to fighting for the rights of investors and ensuring that companies operate with honesty and transparency. If you believe that you have been a victim of securities fraud, contact the Schall Law Firm for a free consultation.
